Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12959 clinical trials for this condition and its sub-types, 151 tagged with Immune system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Immune system disorder
-
Autoimmune disease 313 trials · 4,033 incl. sub-types
47 sub-types
- Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types Sub-types →
- Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types Sub-types →
- Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types Sub-types →
- CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types Sub-types →
- Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types Sub-types →
- Lupus erythematosus 39 trials · 548 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types Sub-types →
- Autoimmune disorder of blood 0 trials · 152 incl. sub-types Sub-types →
- Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types Sub-types →
- Vitiligo 100 trials Sub-types →
- Antiphospholipid syndrome 58 trials · 59 incl. sub-types Sub-types →
- Autoimmune bullous skin disease 7 trials · 55 incl. sub-types Sub-types →
- Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types Sub-types →
- Rheumatic fever 16 trials
- Overlapping connective tissue disease 2 trials · 15 incl. sub-types Sub-types →
- Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types Sub-types →
- Undifferentiated connective tissue syndrome 7 trials
- Autoimmune pulmonary alveolar proteinosis 6 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Anti-glomerular basement membrane disease 5 trials
- Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types Sub-types →
- Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types Sub-types →
- Cryoglobulinemia 3 trials Sub-types →
- Susac syndrome 2 trials
- Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types Sub-types →
- Anti-neutrophil antibody associated vasculitis 1 trial
- Phacolytic glaucoma 1 trial
- Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types Sub-types →
- Jaccoud syndrome 0 trials
- Kimura disease 0 trials
- Reynolds syndrome 0 trials
- Autoerythrocyte sensitization syndrome 0 trials
- Autoimmune disease with susceptibility to mycobacterium tuberculosis 0 trials
- Autoimmune glomerulonephritis 0 trials
- Autoimmune pulmonary disease due to PD-1 deficiency 0 trials
- Autoimmune urticaria 0 trials
- Euthyroid Graves orbitopathy 0 trials
- Multisystem autoimmune disease due to IKAROS gain of function 0 trials
- Non-specific autoimmune brainstem encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune brainstem encephalitis without characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia with characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia without characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis without characteristic antibodies 0 trials
- Tempi syndrome 0 trials
- Type II hypersensitivity reaction disease 0 trials
-
Leukocyte disorder 6 trials · 3,572 incl. sub-types
23 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Immune system cancer 0 trials · 3,121 incl. sub-types
25 sub-types
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
- Plasma cell myeloma 1,105 trials · 1,128 incl. sub-types Sub-types →
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Lymphatic system cancer 4 trials · 69 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- B-cell childhood acute lymphoblastic leukemia 37 trials
- T-cell childhood acute lymphocytic leukemia 10 trials
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types Sub-types →
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
- Breast diffuse large B-cell lymphoma 1 trial
- Colon Burkitt lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric mantle cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Mast cell sarcoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
- Solitary plasmacytoma of chest wall 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,761 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Inflammatory bowel disease 429 trials · 1,079 incl. sub-types
40 sub-types
- Colitis 41 trials · 677 incl. sub-types Sub-types →
- Crohn disease 561 trials · 567 incl. sub-types Sub-types →
- Proctitis 2 trials · 21 incl. sub-types Sub-types →
- Inflammatory bowel disease 1 3 trials
- Undetermined colitis 3 trials
- Ulcerative proctosigmoiditis 2 trials
- ALPI-related inflammatory bowel disease 0 trials
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- TRIM22-related inflammatory bowel disease 0 trials
- Cap polyposis 0 trials
- Cutaneous photosensitivity-lethal colitis syndrome 0 trials
- Inflammatory bowel disease (infantile ulcerative colitis) 31, autosomal recessive 0 trials
- Inflammatory bowel disease 10 0 trials
- Inflammatory bowel disease 11 0 trials
- Inflammatory bowel disease 12 0 trials
- Inflammatory bowel disease 13 0 trials
- Inflammatory bowel disease 14 0 trials
- Inflammatory bowel disease 15 0 trials
- Inflammatory bowel disease 16 0 trials
- Inflammatory bowel disease 17 0 trials
- Inflammatory bowel disease 18 0 trials
- Inflammatory bowel disease 19 0 trials
- Inflammatory bowel disease 2 0 trials
- Inflammatory bowel disease 20 0 trials
- Inflammatory bowel disease 21 0 trials
- Inflammatory bowel disease 22 0 trials
- Inflammatory bowel disease 23 0 trials
- Inflammatory bowel disease 24 0 trials
- Inflammatory bowel disease 26 0 trials
- Inflammatory bowel disease 27 0 trials
- Inflammatory bowel disease 29 0 trials
- Inflammatory bowel disease 3 0 trials
- Inflammatory bowel disease 30 0 trials
- Inflammatory bowel disease 4 0 trials
- Inflammatory bowel disease 5 0 trials
- Inflammatory bowel disease 6 0 trials
- Inflammatory bowel disease 7 0 trials
- Inflammatory bowel disease 8 0 trials
- Inflammatory bowel disease 9 0 trials
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
-
Hypersensitivity reaction disease 32 trials · 1,022 incl. sub-types
10 sub-types
- Allergic disease 178 trials · 966 incl. sub-types Sub-types →
- Anaphylaxis 26 trials · 27 incl. sub-types Sub-types →
- Type IV hypersensitivity disease 0 trials · 18 incl. sub-types Sub-types →
- Hypersensitivity vasculitis 0 trials · 16 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- IgE responsiveness, atopic 9 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Progestogen hypersensitivity 3 trials
- Pseudoallergy 0 trials Sub-types →
- Type II hypersensitivity reaction disease 0 trials
-
Immunodeficiency disease 55 trials · 776 incl. sub-types
95 sub-types
- T-cell immunodeficiency 4 trials · 484 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Myalgic encephalomeyelitis/chronic fatigue syndrome 73 trials
- Combined immunodeficiency 3 trials · 57 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types Sub-types →
- GATA2 deficiency with susceptibility to MDS/AML 5 trials · 8 incl. sub-types Sub-types →
- Idiopathic CD4 lymphocytopenia 7 trials
- IKBKG-related immunodeficiency with or without ectodermal dysplasia 0 trials · 4 incl. sub-types Sub-types →
- Immunodeficiency due to selective anti-polysaccharide antibody deficiency 2 trials
- IRF4-related immune disorder 1 trial Sub-types →
- PTEN harmartoma tumor syndrome with immune disorder 1 trial
- Immunodeficiency 23 1 trial
- Immunodeficiency 31B 1 trial
- DNAJC21-related Shwachman Diamond syndrome 0 trials
- DOCK2 deficiency 0 trials
- FADD-related immunodeficiency 0 trials
- FASLG-related immunodeficiency 0 trials
- FNIP1-associated syndrome 0 trials
- Shwachman-Diamond syndrome 1 0 trials
- TFRC-related combined immunodeficiency 0 trials
- TNFRSF9-related immunodeficiency 0 trials Sub-types →
- Wiskott-Aldrich syndrome 2 0 trials
- Wiskott-Aldrich syndrome, autosomal dominant form 0 trials
- Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 0 trials
- Chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency 0 trials
- Cryptosporidiosis-chronic cholangitis-liver disease syndrome 0 trials
- Hatipoglu immunodeficiency syndrome 0 trials
- Hypoproteinemia, hypercatabolic 0 trials
- Immune deficiency due to impaired neutrophil phagocytosis and migration 0 trials
- Immunodeficiency 101 (varicella zoster virus-specific) 0 trials
- Immunodeficiency 102 0 trials
- Immunodeficiency 106, susceptibility to viral infections 0 trials
- Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection 0 trials
- Immunodeficiency 112 0 trials
- Immunodeficiency 113 with autoimmunity and autoinflammation 0 trials
- Immunodeficiency 114, folate-responsive 0 trials
- Immunodeficiency 115 with autoinflammation 0 trials
- Immunodeficiency 117 0 trials
- Immunodeficiency 118 0 trials
- Immunodeficiency 119 0 trials
- Immunodeficiency 11b with atopic dermatitis 0 trials
- Immunodeficiency 121 with autoinflammation 0 trials
- Immunodeficiency 122 0 trials
- Immunodeficiency 123 with HPV-related verrucosis 0 trials
- Immunodeficiency 125 0 trials
- Immunodeficiency 126, susceptibility to 0 trials
- Immunodeficiency 127 0 trials
- Immunodeficiency 128 0 trials
- Immunodeficiency 132b 0 trials
- Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy 0 trials
- Immunodeficiency 134 (Epstein-Barr virus-specific) 0 trials
- Immunodeficiency 14b, autosomal recessive 0 trials
- Immunodeficiency 15a 0 trials
- Immunodeficiency 35 0 trials
- Immunodeficiency 45 0 trials
- Immunodeficiency 53 0 trials
- Immunodeficiency 57 0 trials
- Immunodeficiency 60 0 trials
- Immunodeficiency 62 0 trials
- Immunodeficiency 63 with lymphoproliferation and autoimmunity 0 trials
- Immunodeficiency 64 0 trials
- Immunodeficiency 65, susceptibility to viral infections 0 trials
- Immunodeficiency 66 0 trials
- Immunodeficiency 67 0 trials
- Immunodeficiency 69 0 trials
- Immunodeficiency 70 0 trials
- Immunodeficiency 72 with autoinflammation 0 trials
- Immunodeficiency 74, COVID-19-related, X-linked 0 trials
- Immunodeficiency 75 0 trials
- Immunodeficiency 76 0 trials
- Immunodeficiency 77 0 trials
- Immunodeficiency 78 with autoimmunity and developmental delay 0 trials
- Immunodeficiency 80 with or without congenital cardiomyopathy 0 trials
- Immunodeficiency 81 0 trials
- Immunodeficiency 82 with systemic inflammation 0 trials
- Immunodeficiency 84 0 trials
- Immunodeficiency 85 and autoimmunity 0 trials
- Immunodeficiency 86 0 trials
- Immunodeficiency 87 and autoimmunity 0 trials
- Immunodeficiency 88 0 trials
- Immunodeficiency 89 and autoimmunity 0 trials
- Immunodeficiency 91 and hyperinflammation 0 trials
- Immunodeficiency 92 0 trials
- Immunodeficiency 93 and hypertrophic cardiomyopathy 0 trials
- Immunodeficiency 95 0 trials
- Immunodeficiency 96 0 trials
- Immunodeficiency 97 with autoinflammation 0 trials
- Immunodeficiency 98 with autoinflammation, X-linked 0 trials
- Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias 0 trials
- Immunodeficiency due to CD25 deficiency 0 trials
- Lymphoproliferative syndrome 1 0 trials
- Primary immunodeficiency due to calcium channel deficiency 0 trials
- Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency 0 trials
- Pyogenic bacterial infections due to MyD88 deficiency 0 trials
-
Lymphoid system disorder 1 trial · 744 incl. sub-types
5 sub-types
- Lymphatic system disorder 30 trials · 707 incl. sub-types Sub-types →
- Tonsillitis 23 trials · 27 incl. sub-types Sub-types →
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Tonsil neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Peritonsillar abscess 4 trials
-
Psoriasis 379 trials
3 sub-types
- Pustular psoriasis 6 trials · 39 incl. sub-types Sub-types →
- Guttate psoriasis 2 trials
- Psoriasis 2 0 trials
-
Inborn error of immunity 121 trials · 343 incl. sub-types
40 sub-types
- Lymphoproliferative syndrome 69 trials · 99 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types Sub-types →
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Familial isolated congenital asplenia 6 trials
- Chronic mucocutaneous candidiasis 4 trials Sub-types →
- Immunoglobulin heavy chain deficiency 0 trials · 2 incl. sub-types Sub-types →
- A20 haploinsufficiency 1 trial
- BENTA disease 1 trial
- Immuno-osseous dysplasia 0 trials · 1 incl. sub-types Sub-types →
- Immunodysregulation with variable immunodeficiency and autoimmunity 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- NK cell deficiency 0 trials
- Say-Barber-Miller syndrome 0 trials
- T cell and NK cell immunodeficiency 0 trials
- T-cell immunodeficiency with epidermodysplasia verruciformis 0 trials
- X-linked immunoneurologic disorder 0 trials
- Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity 0 trials
- Combined immunodeficiency due to moesin deficiency 0 trials
- Combined immunodeficiency with faciooculoskeletal anomalies 0 trials
- Dendritic cell deficiency 0 trials
- Ectodermal dysplasia and immune deficiency 0 trials Sub-types →
- Hepatic veno-occlusive disease-immunodeficiency syndrome 0 trials
- Immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency 0 trials
- Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 0 trials
- Immunodeficiency 28 0 trials
- Immunodeficiency 33 0 trials
- Immunodeficiency 37 0 trials Sub-types →
- Immunodeficiency 39 0 trials
- Immunodeficiency 47 0 trials
- Immunodeficiency 49 0 trials
- Immunodeficiency with defective T-cell response to interleukin 1 0 trials
- Immunodeficiency, X-linked, with deficiency of 115,000 Dalton surface glycoprotein 0 trials
- Inflammatory bowel disease-recurrent sinopulmonary infections syndrome 0 trials
- Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 0 trials
- Properdin deficiency, X-linked 0 trials
- Recurrent infections associated with rare immunoglobulin isotypes deficiency 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Graft versus host disease 186 trials · 300 incl. sub-types
2 sub-types
- Chronic graft versus host disease 118 trials
- Acute graft versus host disease 86 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Spondyloarthropathy 121 trials · 198 incl. sub-types
3 sub-types
- Ankylosing spondylitis 109 trials · 113 incl. sub-types Sub-types →
- Kummell disease 1 trial
- Hypermobility of coccyx 0 trials
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Phagocytic cell dysfunction 1 trial · 76 incl. sub-types
7 sub-types
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Defective phagocytic cell engulfment 0 trials · 37 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Defective phagocytic cell chemotaxis 0 trials
- Defective phagocytic cell opsonization 0 trials
- Familial lipochrome histiocytosis 0 trials
- Phagocytosis, plasma-related defect 1N 0 trials
-
Cytokine release syndrome 33 trials
-
Immunoproliferative disorder 18 trials
-
Familial Mediterranean fever 15 trials
2 sub-types
-
Immunodeficiency-related disorder 1 trial · 15 incl. sub-types
1 sub-type
- AIDS-related disorder 3 trials · 14 incl. sub-types Sub-types →
-
Twin to twin transfusion syndrome 14 trials
1 sub-type
-
22q11.2 deletion syndrome 7 trials · 13 incl. sub-types
4 sub-types
- DiGeorge syndrome 11 trials
- Velocardiofacial syndrome 4 trials
- Chromosome 22q11.2 deletion syndrome, distal 0 trials
- Congenital unilateral hypoplasia of depressor anguli oris 0 trials
-
Cryopyrin-associated periodic syndrome 10 trials
3 sub-types
- CINCA syndrome 4 trials
- Muckle-Wells syndrome 3 trials
- Familial cold autoinflammatory syndrome 3 trials Sub-types →
-
Acquired immunodeficiency 5 trials
2 sub-types
- Good syndrome 0 trials
- Acquired adult-onset immunodeficiency 0 trials
-
Anti-HLA hyperimmunization 3 trials
-
6 sub-types
- Proteasome-associated autoinflammatory syndrome 1 1 trial
- Proteasome-associated autoinflammatory syndrome 2 0 trials
- Proteasome-associated autoinflammatory syndrome 3 0 trials
- Proteasome-associated autoinflammatory syndrome 4 0 trials
- Proteasome-associated autoinflammatory syndrome 5 0 trials
- Proteasome-associated autoinflammatory syndrome 6 0 trials
-
Roifman syndrome 1 trial
-
Aggressive insulitis 1 trial
-
Transcobalamin II deficiency 1 trial
-
CADINS disease 0 trials
-
Vici syndrome 0 trials
-
Autosomal recessive osteopetrosis 7 0 trials
-
Benign insulitis 0 trials
-
Cytokine receptor deficiency 0 trials
-
Epidermodysplasia verruciformis 0 trials
1 sub-type
-
Erythroderma desquamativum 0 trials
-
Immune system organ benign neoplasm 0 trials
3 sub-types
- Benign neoplasm of lymph node 0 trials
- Benign neoplasm of spleen 0 trials Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 517 trials in this tab.
-
Cell therapy targets a marker on myeloma cells
Cure Stopped earlyResearchers are testing a cell therapy called OPC-415 in adults with multiple myeloma that has come back or stopped responding to standard treatments. Participants must have the MMG49 antigen on their cancer cells and have already tried at least two prior regimens. The trial meas…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Can engineered immune cells outsmart Treatment-Resistant myeloma?
Cure Stopped earlyThis early-stage trial is testing an experimental therapy called LCAR-BCDR, which uses a patient's own immune cells that have been engineered to recognize and attack a protein called BCMA found on myeloma cells. The study aims to see if this treatment is safe and tolerable, and w…
Phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Can a Chemo-Antibody combo beat a tough leukemia?
Cure Stopped earlyThis phase II trial is testing whether adding the targeted antibody-drug inotuzumab ozogamicin to a standard chemotherapy regimen (Hyper-CVAD) improves outcomes for adults with B-cell acute lymphoblastic leukemia. The study enrolls people with newly diagnosed or recently remitted…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
Disease control Stopped earlyResearchers are testing RVU120, an experimental oral drug, in adults with acute myeloid leukemia (AML) that has come back or stopped responding to treatment, or with high-risk myelodysplastic syndrome (MDS). The drug blocks two enzymes called CDK8 and CDK19, which may play a role…
Phase 1 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a CDK8/CDK19 blocker help when leukemia and MDS return?
Disease control Stopped earlyResearchers are testing an experimental drug called RVU120 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or stopped responding to treatment. RVU120 blocks two proteins, CDK8 and CDK19, that may help cancer cells grow. T…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Stopped earlyThis Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Double-Drug attack on Hard-to-Treat lymphomas
Disease control Stopped earlyResearchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…
Phase 1/2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Sjögren's drug ASP5502 enters first human tests
Disease control Stopped earlyThis early-stage study tested a new oral drug, ASP5502, for primary Sjögren's syndrome, an autoimmune condition causing dry eyes and mouth. It involved 116 healthy adults and patients to check safety and how the body processes the drug. The study was terminated, but results may g…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control Stopped earlyThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immune cell therapy aims to prevent leukemia return after transplant
Disease control Stopped earlyThis early-phase trial tests a new cell therapy called BSB-1001 in 38 adults with high-risk blood cancers (AML, ALL, or MDS) who are getting a stem cell transplant. BSB-1001 is made from donor immune cells that are modified to attack a specific marker on cancer cells. The goal is…
Phase 1/2 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a lung drug stop transplant rejection? new trial tests Alpha-1 antitrypsin for GVHD
Disease control Stopped earlyThis study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…
Phase 2/3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control Stopped earlyThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase 2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Which eczema drug wins? a Head-to-Head test aims to find out
Disease control Stopped earlyThis trial compares two approved eczema drugs, upadacitinib and dupilumab, in people with moderate-to-severe atopic dermatitis. Researchers will measure how well each drug clears the skin and improves quality of life, including itch and sleep. The study aims to confirm earlier fi…
Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New shot aims to keep insulin flowing in type 1 diabetes
Disease control Stopped earlyThis study tests a drug called Diamyd in people aged 12 to 29 who were recently diagnosed with type 1 diabetes and have a specific genetic type (HLA DR3-DQ2). The goal is to see if Diamyd can help the body keep making its own insulin, which could improve blood sugar control and r…
Phase 3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at leukemia that evades standard therapy
Disease control Stopped earlyThis trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo CAR-T therapy targets multiple cancer proteins
Disease control Stopped earlyThis trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participa…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Stopped earlyThis study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…
Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
Disease control Stopped earlyThis study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Stopped earlyThis study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New CAR t combo takes on tough leukemia
Disease control Stopped earlyThis early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Double-Barreled immune attack aims to wipe out T-ALL
Disease control Stopped earlyThis early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Experimental combo for tough leukemia shows promise in early trial
Disease control Stopped earlyThis pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene therapy aims to fix bone marrow failure in fanconi anemia
Disease control Stopped earlyThis trial tests a gene therapy for Fanconi anemia, a rare genetic disorder that causes bone marrow failure and increases cancer risk. Participants receive their own stem cells that have been genetically corrected with a lentiviral vector to fix the faulty FANCA gene. The study e…
Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Stopped earlyThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for recurring c. diff: which treatment works best?
Disease control Stopped earlyThis study tested three different antibiotic regimens for people with recurrent Clostridium difficile infection (C. diff), a serious gut infection that keeps coming back. The goal was to see if newer drugs like fidaxomicin or a tapered/pulsed course of vancomycin work better than…
Phase 4 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Stopped earlyThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could a daily pill stop hereditary angioedema attacks?
Disease control Stopped earlyThis trial tests whether an experimental oral medication, deucrictibant, can reduce the number of swelling attacks in people with hereditary angioedema (HAE) types I and II. Participants take either a low or high dose of the drug or a placebo for 12 weeks, and then may continue o…
Phase 2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental drug targets tough blood cancers in first human trial
Disease control Stopped earlyThis early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a daily pill shrink the spleen in myelofibrosis?
Disease control Stopped earlyThis phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Lupus skin drug trial halted early – only 8 volunteers joined
Disease control Stopped earlyThis study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The trial was stopped early and only enrolled 8 people instead of the planned 48, so results…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control Stopped earlyThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can stem cell vesicles heal Crohn's fistulas?
Disease control Stopped earlyThis early-phase trial tests whether ExoFlo, a product made from extracellular vesicles derived from donor bone marrow stem cells, can safely treat perianal fistulas in people with Crohn's disease. The study enrolls adults aged 18-75 who have had Crohn's for at least six months a…
Phase 1/2 • Sponsor: Direct Biologics, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new antibody calm the immune attack in CIDP?
Disease control Stopped earlyThis trial is testing whether an experimental drug called batoclimab can help adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system damages nerves, causing weakness and disability. Participants receive either batoclimab o…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new biologic tame lupus flares?
Disease control Stopped earlyThis trial is testing whether an experimental biologic called MK-6194 can reduce disease activity in adults with systemic lupus erythematosus (SLE), an autoimmune condition that causes inflammation and organ damage. Participants receive either MK-6194 or a placebo as an injection…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a vitamin B3 pill help kids with colitis?
Disease control Stopped earlyThis study tests whether a daily supplement called nicotinamide riboside (a form of vitamin B3) can help children with mild to moderate ulcerative colitis. About 40 kids will take either the supplement or a placebo for 6 to 12 months, alongside their usual treatment. The main goa…
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new hip implant stand the test of time?
Disease control Stopped earlyThis study follows about 300 people who receive a hip replacement using the GTS cementless stem, a type of implant that anchors to bone without cement. The goal is to see how well the implant performs over up to 10 years, measuring pain, function, and joint stability. Participant…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a gel tame psoriasis? new antibody fragment put to the test
Disease control Stopped earlyThis phase 2 trial is testing whether a topical gel containing ZL-1102, an antibody fragment that blocks IL-17A, can safely and effectively reduce the severity of chronic plaque psoriasis. The study enrolls adults with psoriasis for at least six months and compares different dose…
Phase 2 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Melanoma drug combo trial halted after just 3 patients
Disease control Stopped earlyThis study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Which Pre-Transplant chemo works best for MDS/AML? new trial aims to find out
Disease control Stopped earlyThis phase II trial tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant in adults with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free s…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental MS drug tested in kids, but study halted early
Disease control Stopped earlyThis study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the tria…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New injection aims to stop dangerous psoriasis flares in their tracks
Disease control Stopped earlyThis phase 2 trial tests an injection called TQH2929, a lab-made antibody that blocks inflammation, in 36 adults having a sudden, severe flare of generalized pustular psoriasis (GPP). Half get the drug, half get a placebo. The main goal is to see if the drug clears pustules withi…
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Eczema drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a new drug help preserve insulin production in type 1 diabetes?
Disease control Stopped earlyThis early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants r…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Psoriasis patients switch biologics in new Real-World study
Disease control Stopped earlyThis study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin symptoms and check for side effects over 52 weeks. The goal is to see if guselkumab works sa…
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a once-weekly antibiotic help people with opioid use disorder beat serious infections at home?
Disease control Stopped earlyThis trial tests whether a weekly IV antibiotic called oritavancin, given alongside medication for opioid use disorder, can help people finish treatment for serious infections like bloodstream or bone infections without needing to stay in a nursing facility. The study enrolls adu…
Phase 4 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental antibody aims to quiet spinal inflammation without X-Ray damage
Disease control Stopped earlyThis phase 2 trial tests an experimental drug called JS005 in Chinese adults with active non-radiographic axial spondyloarthritis, a form of inflammatory back pain that does not yet show damage on X-rays. Participants receive either a low, medium, or high dose of JS005 or a place…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a quick quiz end millions of unnecessary penicillin allergies?
Disease control Stopped earlyThis study tests whether a short questionnaire can identify hospitalized patients who were incorrectly labeled as allergic to penicillin. Those deemed low-risk receive a supervised dose of amoxicillin to confirm they can tolerate it. If they do, the allergy label is removed from …
Early phase 1 • Sponsor: Geisinger Clinic • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Rheumatoid arthritis combo drug trial stalls after just 2 patients
Disease control Stopped earlyThis early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions ca…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Liver-Friendly lymphoma treatment? new drug dosing study offers hope
Disease control Stopped earlyThis study tests the safety and best dose of loncastuximab tesirine, a targeted antibody-drug conjugate, in people with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver impairment. The goal is to find a dosi…
Phase 1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Diabetes drug metformin could boost myeloma treatment
Disease control Stopped earlyThis phase 2 trial tests whether adding metformin — a common diabetes medication — to high-dose dexamethasone can improve outcomes for people with multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults over 18 who have failed at lea…
Phase 2 • Sponsor: University of Campinas, Brazil • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients who stop responding to standard therapy
Disease control Stopped earlyThis phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New eczema drug shows promise in Long-Term safety trial for thousands
Disease control Stopped earlyThis study looks at the long-term safety and tolerability of a drug called rocatinlimab for people with moderate-to-severe atopic dermatitis (eczema). It involves over 2,600 adults and teenagers who have already completed a previous rocatinlimab study. Researchers will monitor si…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug ATG-031 targets Hard-to-Treat cancers in first human trial
Disease control Stopped earlyThis study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion…
Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New arthritis drug trial for kids: could filgotinib help?
Disease control Stopped earlyThis study is testing the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA), a condition causing joint pain and swelling. The goal is to see how the drug moves through the body and if it is safe. Ten children with moderate to severe JIA that is not…
Phase 1 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can CML patients pause treatment? new study explores Drug-Free remission
Disease control Stopped earlyThis study looked at 124 adults with chronic myeloid leukemia (CML) who had been on the drug nilotinib for at least 3 years and had very low levels of cancer. First, researchers tested if lowering the nilotinib dose by half for a year could help patients stop treatment entirely. …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a Three-Pronged attack keep High-Risk leukemia at bay?
Disease control Stopped earlyThis phase 1 trial is testing whether a combination of two drugs (venetoclax and azacitidine) followed by donor immune cell infusions can prevent relapse in people with very high-risk acute myeloid leukemia (AML) who have already received a stem cell transplant. The study enrolls…
Phase 1 • Sponsor: Antonio M Jimenez Jimenez • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Stopped earlyThis trial tests a new therapy called CART123 for adults with acute myeloid leukemia (AML) that has not responded to standard treatments or has returned after treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cell…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for vitiligo: experimental drug aims to restore skin color
Disease control Stopped earlyThis study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped earl…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New CAR t cocktail aims to tackle Hard-to-Treat myeloma
Disease control Stopped earlyThis early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so res…
Phase 1 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New cancer pill shows early promise, but trial halted
Disease control Stopped earlyThis early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Iron infusions may boost gut healing in celiac disease
Disease control Stopped earlyThis trial investigates whether adding intravenous iron to standard oral iron supplements can help heal intestinal damage in people with celiac disease who have iron deficiency and gut atrophy. Participants receive either intravenous iron infusions plus oral iron, or oral iron al…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
CAR-T therapy for myeloma shows promise in early trial
Disease control Stopped earlyThis early-stage study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on multiple myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and infusing them back. The study included …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New Two-Target antibody for eczema tested in early trial
Disease control Stopped earlyThis early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either …
Phase 1 • Sponsor: Yellow Jersey Therapeutics AG • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental blood cancer drug trial halted early
Disease control Stopped earlyThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for elderly lymphoma patients: antibody therapy without harsh chemo
Disease control Stopped earlyThis study tests a drug called epcoritamab, given alone or with another drug (lenalidomide), in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy. The goal is to see how well the treatment shrinks tumors and how safe it is. All 111 particip…
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New daily pill aims to tame Crohn's Flare-Ups
Disease control Stopped earlyThis trial investigates whether an oral medication called etrasimod can help people with moderate to severe Crohn's disease who have not responded well to other treatments. Participants take either etrasimod or a placebo daily for up to several years. The study measures improveme…
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a drug cocktail halt bone Cancer's spread after radiation?
Disease control Stopped earlyThis study tests whether adding a three-drug combination (ixazomib, lenalidomide, and dexamethasone) to zoledronic acid after radiation therapy can prevent solitary plasmacytoma of bone from turning into multiple myeloma. Participants receive either the drug combo plus zoledronic…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cell therapy shows promise for tough-to-treat lymphoma
Disease control Stopped earlyThis study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…
Phase 1/2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Placenta cells tested as COVID fighter – but trial stopped early
Disease control Stopped earlyThis early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
Phase 1/2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lymphoma drug combo trial for youth halted after just 5 patients
Disease control Stopped earlyThis early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control Stopped earlyThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New biologic drug brazikumab tested for Crohn's – trial cut short
Disease control Stopped earlyThis study tested brazikumab, an experimental biologic drug, in 89 adults with moderate-to-severe Crohn's disease. Participants received either brazikumab, a placebo, or an active comparator (Humira) to see if the drug could improve symptoms and heal the gut lining. The trial was…
Phase 2/3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug shows promise for Long-Term control of ulcerative colitis
Disease control Stopped earlyThis study looks at the long-term safety of brazikumab, a drug given as a shot every 4 weeks, for people with moderate to severe ulcerative colitis. Participants had already taken part in an earlier study of brazikumab. The goal is to see if the drug remains safe over a longer pe…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental combo for tough leukemia hits early snag
Disease control Stopped earlyThis early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the d…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New injection for ulcerative colitis shows early promise, but trial halted
Disease control Stopped earlyThis early-phase study tested an injectable drug called NP-201 acetate in healthy volunteers and people with mild-to-moderate ulcerative colitis. The goal was to check safety, how the body processes the drug, and early signs of effectiveness. The trial was terminated early, so on…
Phase 1 • Sponsor: NIBEC Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug brazikumab aims to tame ulcerative colitis Flare-Ups
Disease control Stopped earlyThis phase 2 trial tested brazikumab in 242 adults with moderate-to-severe ulcerative colitis. Participants received either brazikumab or a placebo intravenously and then as injections over 54 weeks. The goal was to see if the drug could improve symptoms and heal the colon lining…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ankle implant tracked for Long-Term success in arthritis patients
Disease control Stopped earlyThis study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can IBD patients safely stretch their infusion schedule? new study tests two strategies
Disease control Stopped earlyThis study looks at people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are in deep remission. It compares two methods for gradually increasing the time between infliximab infusions: one based on symptoms and one based on drug levels in the blood. T…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Promising c. diff drug fails to prove benefit in small, halted trial
Disease control Stopped earlyThis study tested whether an extra dose of bezlotoxumab, a drug that blocks the harmful toxin made by C. diff bacteria, could help very sick patients recover after emergency colon surgery. Only 5 people took part before the study was stopped early. The goal was to see if the drug…
Phase 4 • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New universal cell therapy shows promise for Hard-to-Treat blood cancer
Disease control Stopped earlyThis early-stage study tested a new type of cell therapy called LUCAR-B68 in 8 adults with multiple myeloma that had come back or stopped responding to treatment. The therapy targets a protein called BCMA on cancer cells and is designed to be used without needing to match the pat…
Phase 1 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill for ulcerative colitis shows promise, but trial halted early
Disease control Stopped earlyThis study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the da…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smartphone system aims to automate insulin delivery for type 1 diabetes
Disease control Stopped earlyThis study tests an automated insulin delivery system for adults with type 1 diabetes. The system uses a smartphone connected to a continuous glucose monitor and insulin pump to help keep blood sugar levels in a healthy range, especially overnight. Ten participants compare the au…
Sponsor: Sue Brown • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eczema drug study halted early: what we learned about GSK1070806
Disease control Stopped earlyThis study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so res…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to spare seniors from chemo
Disease control Stopped earlyThis phase 2 trial tested a combination of two drugs, venetoclax and rituximab, as a first treatment for people over 60 with mantle cell lymphoma. The goal was to see if this chemo-free approach could shrink or control the cancer. However, the study was stopped early after enroll…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for myelofibrosis patients who failed standard therapy?
Disease control Stopped earlyThis study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo for resistant leukemia shows early promise but trial halted
Disease control Stopped earlyThis pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The …
Phase 2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo therapy for tough lymphoma shows promise but trial halted early
Disease control Stopped earlyThis Phase 2 trial tested a two-step treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by an infusion of CAR-T cells (a type of immune cell therapy). The goal was to se…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for AML after transplant falls short as trial ends early
Disease control Stopped earlyThis study tested whether adding venetoclax and azacitidine after a stem cell transplant could help people with acute myeloid leukemia (AML) live longer. It included adults and teens who had recently received a transplant. The trial was stopped early, so the full benefits and ris…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Eczema drug trial halted midway – what happened?
Disease control Stopped earlyThis study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was t…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill tested for severe transplant complication
Disease control Stopped earlyThis study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control Stopped earlyThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough blood cancers: early trial of ONO-7018 begins
Disease control Stopped earlyThis early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
CML drug combo aims for Treatment-Free remission, but trial stalls
Disease control Stopped earlyThis phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small…
Phase 3 • Sponsor: Sarit Assouline • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
HIV drug switch may boost heart health and trim body fat
Disease control Stopped earlyThis study looked at whether switching from a standard HIV drug combination to a different one (Delstrigo) could improve cholesterol, body fat, and blood sugar in people with HIV. The study planned to enroll 60 adults whose HIV was already well-controlled. Participants were rando…
Phase 4 • Sponsor: Chelsea and Westminster NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control Stopped earlyThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Mini transplant shows promise for blood cancers – but trial ended early
Disease control Stopped earlyThis study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Rheumatoid arthritis drug study halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Botulinum injection trial for arm spasticity halted early
Disease control Stopped earlyThis study tested whether injections of MYOBLOC (botulinum toxin type B) can safely reduce muscle tightness in the arm and hand of adults with spasticity caused by stroke, brain injury, multiple sclerosis, or other conditions. The trial planned to enroll about 300 participants bu…
Phase 2/3 • Sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Promising GVHD prevention trial halted early – too few patients to draw conclusions
Disease control Stopped earlyThis phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Early trial of lenalidomide after transplant for myeloma stopped early
Disease control Stopped earlyThis phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cance…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Eczema drug switch studied after first treatment fails
Disease control Stopped earlyThis study looked at whether a drug called tralokinumab could help adults with eczema who had already tried dupilumab and didn't get enough relief. The plan was to treat 20 people for 24 weeks, but the study was stopped early and only 7 people took part. The main goal was to see …
Phase 4 • Sponsor: Psoriasis Treatment Center of Central New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control Stopped earlyThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental diabetes drug trial halted early
Disease control Stopped earlyThis study tested an experimental drug called TOL-3021 in people with type 1 diabetes to see if it could help preserve the body's ability to produce insulin. The trial enrolled 78 participants aged 12 to 41 who had been diagnosed within the last 5 years. The study was terminated …
Phase 2 • Sponsor: Tolerion, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early
Disease control Stopped earlyThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whet…
Phase 2/3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough leukemias? trial of vodobatinib begins, then stops
Disease control Stopped earlyThis study tested a new drug called Vodobatinib (K0706) in people with chronic myeloid leukemia or a related leukemia who had not responded to at least three other treatments. The trial was split into parts: first in healthy volunteers to check safety, then in patients to find th…
Phase 1/2 • Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control Stopped earlyThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for elderly myeloma patients: Steroid-Free combo shows promise
Disease control Stopped earlyThis study tested a combination of two drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in elderly patients (65 and older) whose multiple myeloma had returned after previous treatments. The goal was to see if this gentler approach could effectively control …
Phase 2 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug for rare skin disease fails to reach goal
Disease control Stopped earlyThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cream aims to stop vitiligo relapse after repigmentation
Disease control Stopped earlyThis trial tested a cosmetic cream called RV5098A to see if it could help adults with vitiligo keep their facial pigmentation after successful repigmentation treatment. Vitiligo causes white patches on the skin, and even after treatment, about 40% of people lose color again withi…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
CRISPR's diabetes cell therapy trial ends early
Disease control Stopped earlyThis early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. Th…
Phase 1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising diabetes delay study halted due to lack of participants
Disease control Stopped earlyThis study tested a low dose of a drug called ATG to see if it could delay or prevent type 1 diabetes in people at high risk. Only 2 people enrolled, so the study was stopped early. The goal was to measure how long it took for participants to develop full-blown diabetes.
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Old allergy drug may help repair nerves in MS patients
Disease control Stopped earlyThis study tested whether clemastine fumarate, an allergy medication, could improve eye movement problems in people with multiple sclerosis (MS). The trial planned to enroll 80 MS patients with a specific eye condition called internuclear ophthalmoparesis, but was terminated earl…
Phase 3 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising vasculitis drug trial halted early
Disease control Stopped earlyThis study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to keep multiple myeloma in check
Disease control Stopped earlyThis study looked at whether adding the drug ixazomib to lenalidomide and dexamethasone can help people with multiple myeloma stay in remission longer after their first round of chemotherapy. About 141 adults who had already completed 3 cycles of a bortezomib-based regimen took p…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Placenta cell therapy shows promise for tough transplant complication
Disease control Stopped earlyThis trial tested a treatment made from placenta cells (called decidua stroma cells) in 12 adults who had severe graft-versus-host disease (GVHD) after a stem cell transplant and did not respond to steroids. Patients received two doses of the cells or the best available standard …
Phase 2 • Sponsor: Mats Remberger • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo targets Hard-to-Treat lymphoma
Disease control Stopped earlyThis study tested two experimental drugs, maplirpacept and glofitamab, given after a single dose of obinutuzumab, in adults with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatments. Participants had already tried at least two standard ther…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug tested for Post-Transplant blood cancers — but study halted early
Disease control Stopped earlyThis pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…
Phase 2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Tonsil infection showdown: surgery vs. drainage
Disease control Stopped earlyThis study looked at the best way to treat a tonsillar abscess, a painful infection near the tonsils. It compared two treatments: removing the tonsils (tonsillectomy) versus draining the pus with a needle under local anesthesia. The goal was to see which method works better to cl…
Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill aims to tame ulcerative colitis Flare-Ups
Disease control Stopped earlyThis study tested an experimental daily tablet called VTX002 in people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 213 participants were randomly assigned to receive one of two doses of VTX002 or a placebo for 13 weeks, with the option …
Phase 2 • Sponsor: Oppilan Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New treatment for shrimp and cashew allergies shows promise, but study stopped early
Disease control Stopped earlyThis study tested a treatment called oral immunotherapy (OIT) for people with shrimp or cashew allergies. Participants slowly ate increasing amounts of the allergen to build tolerance. The study aimed to see how immune cells change over a year. It included 58 people aged 7 to 55,…
Phase 2 • Sponsor: Sayantani B. Sindher • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control Stopped earlyThis study tested whether hydroxychloroquine, a drug used for lupus and arthritis, could help control ANCA vasculitis—a group of autoimmune diseases that cause blood vessel inflammation. Adults with mild disease activity were randomly assigned to receive hydroxychloroquine or a p…
Phase 4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Batoclimab shows promise for thyroid eye disease in extension study
Disease control Stopped earlyThis study is for people who finished earlier trials of batoclimab for thyroid eye disease. It has two parts: one watches how long benefits last without treatment, and the other gives batoclimab to see if it helps more patients. The goal is to see if the drug can control eye bulg…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising myeloma combo trial halted after just 4 patients
Disease control Stopped earlyThis very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped earl…
Phase 1 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Monthly MS injection aims to halt disability progression
Disease control Stopped earlyThis study tested a long-acting form of glatiramer acetate (GA Depot) given as a monthly shot to people with primary progressive multiple sclerosis (PPMS). The goal was to see if it could safely slow down worsening disability. The trial was stopped early, but it involved 30 adult…
Phase 2 • Sponsor: Mapi Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple-Drug attack on tough leukemia shows promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into r…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill for tough blood cancers tested in early trial
Disease control Stopped earlyThis early-stage study tested an oral drug called AUR104 in 9 adults with certain blood cancers (lymphomas and leukemia) that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The trial was terminated ear…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Stem cells tested for tough Crohn's fistulas – but trial stopped early
Disease control Stopped earlyThis study tested whether stem cells from donated bone marrow could heal fistulas (abnormal tunnels) in people with Crohn's disease who had a pouch after colon removal. The trial planned to enroll 24 adults but was terminated early, so we don't have clear results on safety or hea…
Phase 1/2 • Sponsor: Anthony Lembo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Stem cells tested for a tough Crohn's complication – but trial stopped early
Disease control Stopped earlyThis study tested whether stem cells from donated bone marrow could safely heal rectovaginal fistulas in women with Crohn's disease. These fistulas are abnormal connections between the rectum and vagina that cause pain, infections, and poor quality of life. The trial planned to e…
Phase 1/2 • Sponsor: Anthony Lembo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could stem cells heal painful fistulas in kids with Crohn's?
Disease control Stopped earlyThis early-phase study tested whether injecting stem cells from donated bone marrow could help heal perianal fistulas in teenagers with Crohn's disease. Six patients aged 13-17 received injections of 75 million stem cells directly into the fistula tract, with a possible second do…
Phase 1 • Sponsor: Anthony Lembo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Stem cells injected into gut to fight Crohn's – but trial stops early
Disease control Stopped earlyThis early-phase study tested whether injecting donor stem cells directly into the colon could help people with severe Crohn's colitis that didn't respond to standard treatments. Only 7 people took part before the study was stopped early. The main goal was to check safety, but be…
Phase 1/2 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Stem cells tested for tough bowel disease – but trial stopped early
Disease control Stopped earlyThis early-stage study tested whether injecting donor stem cells (remestemcel-L) into the colon could help people with severe ulcerative colitis that hadn't responded to other treatments. Only 7 adults took part before the trial was stopped early. The main goal was to check safet…
Phase 1/2 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control Stopped earlyThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Phase 1/2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Hydroxychloroquine's effect on arteries in APS studied, but trial cut short
Disease control Stopped earlyThis study looked at whether hydroxychloroquine (Plaquenil) could improve artery function in people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. Researchers planned to give either hydroxychloroquine or a placebo to 25 participants and mea…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Stem cell shot aims to heal painful Crohn's fistulas
Disease control Stopped earlyThis early-stage study tested whether injecting donor stem cells directly into fistulas (abnormal tunnels) could help people with Crohn's disease. The trial planned to enroll 25 adults but was terminated early. The goal was to check safety and see if the treatment could lead to c…
Phase 1/2 • Sponsor: Anthony Lembo • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Crohn's surgery showdown: which technique wins?
Disease control Stopped earlyThis study compared two surgical methods for removing diseased intestine in people with Crohn's disease: one that cuts the main artery high up, and one that spares the mesentery (the tissue holding the intestine). The goal was to see which technique better prevents the disease fr…
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug telitacicept tested for MS Flare-Ups
Disease control Stopped earlyThis phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
Phase 2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental gene therapy aims to fix immune system in rare childhood disease
Disease control Stopped earlyThis early-phase trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off bacteria and fungi. The treatment involved taking the patient's own blood stem cells, adding a corrected gene, and infusin…
Phase 1/2 • Sponsor: Genethon • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental gene therapy targets rare immune disorder
Disease control Stopped earlyThis trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off infections. The treatment involved taking the patient's own blood stem cells, adding a working copy of the faulty gene, and returning …
Phase 1/2 • Sponsor: Genethon • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental combo for Graft-Versus-Host disease fails to enroll
Disease control Stopped earlyThis study tested a mix of drugs (cyclophosphamide, sirolimus, low-dose IL-2, and azacitidine) to treat severe graft-versus-host disease that didn't respond to steroids. Only 3 patients were enrolled before the trial was stopped early. The goal was to see if the treatment could c…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control Stopped earlyThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental lymphoma drug CPO107 tested in small early trial
Disease control Stopped earlyThis early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…
Phase 1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising drug for hand and foot blisters falls short in early trial
Disease control Stopped earlyThis study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug gentulizumab tested for tough blood cancers – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control Stopped earlyThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lupus flare prevention drug trial halted early
Disease control Stopped earlyThis study tested a drug called PRV-3279 to see if it could prevent lupus flares in people with active systemic lupus erythematosus (SLE). The trial included 28 adults with moderate to severe lupus who had improved after steroid treatment. The study was terminated early, so resul…
Phase 2 • Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell transplant study halted early: which prep works best?
Disease control Stopped earlyThis study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…
Phase 3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental combo for tough lymphoma shows early promise, but trial halted
Disease control Stopped earlyThis early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest do…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo after transplant shows promise for High-Risk blood cancers
Disease control Stopped earlyThis study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental chemo cocktail targets resistant leukemia
Disease control Stopped earlyThis study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New lymphoma drug trial halted early after testing in 18 patients
Disease control Stopped earlyThis early-stage trial tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin Lymphoma that had come back or not responded to prior treatments. The main goals were to check safety and find the right dose. The study was termin…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New stem cell method aims to protect kids with rare immune disease
Disease control Stopped earlyThis study tested a way to improve stem cell transplants for children with combined immunodeficiency (CID), a condition where the immune system doesn't work properly. The approach removed certain naive cells from the donor stem cells to try to prevent graft-versus-host disease (a…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Leukemia drug spectrila tested in adults: phase 2 trial looks at drug levels and safety
Disease control Stopped earlyThis study tested the drug Spectrila (a form of L-asparaginase) in 40 adults aged 18-55 with newly diagnosed B-cell acute lymphoblastic leukemia. The goal was to see if the drug reached effective levels in the blood and to check its safety and immune response. The trial was termi…
Phase 2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Crohn's drug trial halted early: what happened?
Disease control Stopped earlyThis study was designed to see if brazikumab is safe and tolerable over the long term for people with moderate to severe Crohn's disease. It enrolled 18 participants who had previously been in a related study. The trial was terminated early, meaning it did not reach its planned e…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Tiny MS drug safety study stopped early – no results yet
Disease control Stopped earlyThis was a very early Phase 1 study testing the safety of a drug called bryostatin in just 4 people with multiple sclerosis. Participants received multiple doses over 26 weeks. The study was terminated, meaning it stopped early, so we don't have clear results on whether the drug …
Phase 1 • Sponsor: Robert Fox • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control Stopped earlyThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase 1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug shows promise for rare immune disorder, but study cut short
Disease control Stopped earlyThis study tested the long-term safety and effectiveness of a drug called CDZ173 in people with APDS/PASLI, a rare genetic condition that causes a weak immune system and swollen lymph nodes. The 37 participants had already taken CDZ173 or a similar drug in a previous study. The t…
Phase 2/3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
CBD-Hydroxychloroquine combo tested for arthritis pain – but trial ends early
Disease control Stopped earlyThis study tested a combination pill called IHL-675A, which contains cannabidiol (CBD) and hydroxychloroquine, in people with rheumatoid arthritis. The goal was to see if it safely reduces pain and improves daily function. The trial planned to enroll 128 volunteers but was termin…
Phase 2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising psoriasis drug trial halted early – what now?
Disease control Stopped earlyThis study tested a drug called imsidolimab for adults with generalized pustular psoriasis (GPP), a rare and painful skin condition. The trial aimed to see if the drug is safe and works over the long term. However, the study was terminated early, so we have less information than …
Phase 3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control Stopped earlyThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase 1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Stem cell study for older myeloma patients halted early
Disease control Stopped earlyThis study looked at two different high-dose chemotherapy treatments for people aged 65 and older with multiple myeloma, a type of blood cancer. Participants received either the standard chemotherapy (melphalan) or a combination of melphalan and another drug (bortezomib) before a…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control Stopped earlyThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental cancer drug BR105 trial stopped early
Disease control Stopped earlyThis early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug for tough leukemias hits dead end
Disease control Stopped earlyThis early-phase trial tested an oral drug called NMS-03592088 in 63 adults with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) that had come back or not responded to standard treatments. The goal was to check safety, find the right dose, and see if it cou…
Phase 1/2 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug voruciclib tested in desperate blood cancer patients
Disease control Stopped earlyThis early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…
Phase 1 • Sponsor: MEI Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
CAR-T trial for blood cancer halted after single patient
Disease control Stopped earlyThis study tested a new CAR-T cell therapy for people with multiple myeloma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells to target cancer cells. The trial was stopped early and only enrolled one person, so we have very limit…
Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental combo for MDS and AML shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was…
Phase 1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cord blood immune cells tested against tough leukemia
Disease control Stopped earlyThis early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…
Phase 1/2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug hope for painful hand and foot pustules
Disease control Stopped earlyThis trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…
Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Computer-tailored drug dosing aims to tame Crohn's in kids
Disease control Stopped earlyThis trial tested whether a computer program that customizes infliximab doses based on blood tests can help children and young adults with Crohn's disease reach better drug levels than standard dosing. Only 6 participants were enrolled before the study was stopped early. The goal…
Phase 2/3 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental donor CAR-T therapy tested in lymphoma – trial halted early
Disease control Stopped earlyThis early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…
Phase 1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Bile acid hope for pouchitis patients fizzles in early study
Disease control Stopped earlyThis study tested whether a bile acid supplement called UDCA could reduce inflammation and improve quality of life in people with pouchitis, a complication after ulcerative colitis surgery. Only 2 participants were enrolled before the study was terminated. The goal was to see if …
Phase 2/3 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to tame gluten reaction in celiac disease
Disease control Stopped earlyThis study tested an experimental drug called KAN-101 in people with celiac disease. The goal was to see if it could safely reduce the immune response to gluten. The trial included 128 participants and was split into phases to check safety and how the body processes the drug. How…
Phase 1/2 • Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR T-Cell therapy targets rare B-Cell cancers
Disease control Stopped earlyThis phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for rare kidney disease? trial tests imlifidase
Disease control Stopped earlyThis study tested a new drug called imlifidase for people with severe Goodpasture disease, a rare condition where the immune system attacks the kidneys and lungs. The trial compared imlifidase plus standard care to standard care alone in 50 adults with poor kidney function. The g…
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to wipe out hidden leukemia cells
Disease control Stopped earlyThis phase II trial tested adding asciminib (ABL001) to standard tyrosine kinase inhibitor therapy in 7 people with chronic myeloid leukemia who still had traces of cancer. The goal was to see if the combination could eliminate remaining cancer cells. The study was terminated ear…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo tried for tough blood cancers
Disease control Stopped earlyThis early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental CAR t combo trial halted early – only 2 patients enrolled
Disease control Stopped earlyThis study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combi…
Phase 2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Promising combo for lymphoma hits early snag – trial stopped
Disease control Stopped earlyThis phase 2 study tested umbralisib (a PI3K blocker) plus rituximab (an antibody that targets B-cells) as the first treatment for people with follicular or marginal zone lymphoma. The goal was to see how many patients had their tumors disappear completely. Only 18 people enrolle…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Chemo-Free combo for lymphoma shows promise in early trial
Disease control Stopped earlyThis phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and rituximab (Truxima), in 22 people with marginal zone lymphoma, a type of blood cancer. The goal was to see if this chemotherapy-free approach could control the disease with fewer side effects than …
Phase 2 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope: drug may shield brain from CAR T-Cell therapy side effects
Disease control Stopped earlyThis study tested whether the drug anakinra could prevent severe brain inflammation (called ICANS) that sometimes happens after CAR T-cell therapy for certain types of lymphoma. The trial involved 23 adults whose lymphoma had returned or not responded to prior treatments. Researc…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Antifungal drug targets gut fungus in Crohn's patients with genetic risk
Disease control Stopped earlyThis study tested the antifungal drug posaconazole in people with active Crohn's disease who carry a specific gene variant (CARD9 S12N). The goal was to see if reducing a type of fungus in the gut could lower inflammation and improve symptoms. The trial was stopped early and incl…
Phase 4 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control Stopped earlyThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New surgery aims to stop lymphedema in cancer patients
Disease control Stopped earlyThis study tested a surgical method to prevent lymphedema (arm swelling) in people having lymph nodes removed for breast cancer or melanoma. The technique, called axillary reverse mapping with lympho-venous bypass, aims to preserve arm drainage while removing cancer-affected node…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New Triple-Drug approach targets leukemia in vulnerable patients
Disease control Stopped earlyThis early-phase study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The study was stopped early, so resul…
Phase 1 • Sponsor: Brian Jonas • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control Stopped earlyThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for ulcerative colitis? drug trial shows promise
Disease control Stopped earlyThis study tested a drug called vixarelimab in 79 people with moderate to severe ulcerative colitis (UC) who had not responded well to other treatments. The goal was to see if the drug could help control the disease and reduce symptoms like diarrhea and bleeding. The study was st…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Steroid-Free hope? early trial of ruxolitinib for young GVHD patients ends prematurely
Disease control Stopped earlyThis pilot study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. The goal was to see if it could control the disease while avoiding steroi…
Phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cancer drug trial stopped early: only 5 patients enrolled
Disease control Stopped earlyThis study tested the drug pembrolizumab in people with a hard-to-treat type of lymphoma (DLBCL) that has certain genetic changes in the PD-L1 gene. The goal was to see if the drug could shrink tumors. However, the study was stopped early after enrolling only 5 participants, so t…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Tailored drug regimen shows promise for rare blood disorder
Disease control Stopped earlyThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New tech approach aims to prevent repeat hospital stays for diabetes patients
Disease control Stopped earlyThis study tested whether a team-based approach using continuous glucose monitors could help adults with type 1 diabetes better control their blood sugar and avoid another hospital stay after a diabetic ketoacidosis (DKA) episode. Only 2 people enrolled before the study was stopp…
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Melatonin trial for MS halted early – what we know
Disease control Stopped earlyThis study tested whether adding melatonin to the standard drug ocrelizumab could safely slow disability in people with progressive primary multiple sclerosis. The trial was terminated early, so results are limited. Participants were adults aged 18–65 with this type of MS.
Phase 1/2 • Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lupus skin drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising leukemia drug falls short in kids trial
Disease control Stopped earlyThis phase 2 trial tested inotuzumab ozogamicin (Besponsa) in children with B-cell acute lymphoblastic leukemia who had low levels of remaining cancer cells (MRD) despite treatment. The drug targets CD22, a protein on leukemia cells, and delivers a potent toxin. Only 5 children w…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell therapy targets stubborn leukemia in early trial
Disease control Stopped earlyThis early-phase study tested a new treatment called LCAR-AMDR cells in 4 people with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment uses specially engineered immune cells to target two proteins (CLL1 and CD33) on leukemia cells. The…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental CAR t therapy for severe muscle weakness hits early hurdle
Disease control Stopped earlyThis early trial tested an experimental drug called HN2301, a type of CAR T cell therapy made inside the body, for people with refractory myasthenia gravis — a condition causing severe muscle weakness that doesn't respond well to standard treatments. The study planned to enroll 9…
Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Ulcerative colitis drug study halted early
Disease control Stopped earlyThis study looked at the safety and effectiveness of the drug ozanimod for people with moderate to severe ulcerative colitis. It aimed to see if the drug could improve symptoms like diarrhea and rectal bleeding, and how it affected quality of life. The study was terminated early,…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental myeloma drug trial halted early
Disease control Stopped earlyThis study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. Th…
Phase 1/2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control Stopped earlyThis early-phase trial tested a new drug called KRT-232 combined with three standard myeloma drugs (carfilzomib, lenalidomide, and dexamethasone) in 35 patients whose multiple myeloma had returned or stopped responding to treatment. The main goals were to check safety and find th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental drug for rare inflammatory disease shows early promise but trial cut short
Disease control Stopped earlyThis study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe o…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Gut bacteria swap explored as MS treatment in early trial
Disease control Stopped earlyThis early-phase study tested whether a fecal transplant from a healthy donor could be safe and affect the immune system in people with relapsing-remitting multiple sclerosis. Only 5 participants were enrolled before the study was stopped. The goal was to see if changing gut bact…
Phase 1 • Sponsor: Jeffrey Gelfand • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Promising combo for tough blood cancers hits early snag
Disease control Stopped earlyThis study tested a combination of two targeted drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and could shrink tumors. However, the trial was termi…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental combo for tough leukemias shows early promise
Disease control Stopped earlyThis early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo for blood cancer tested in early trial
Disease control Stopped earlyThis early-phase study tested a new drug called modakafusp alfa combined with daratumumab in 15 people with multiple myeloma that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose. The trial was terminated early, so full…
Phase 1/2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental myeloma drug shows promise but trial halted early
Disease control Stopped earlyThis study tested a new drug called modakafusp alfa in 272 people with multiple myeloma that had returned or stopped responding to other treatments. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, but researchers collected dat…
Phase 1/2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody drug takes on tough blood cancers
Disease control Stopped earlyThis early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve …
Phase 1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental myeloma combo trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called modakafusp alfa (TAK-573) combined with standard myeloma treatments in 15 adults with multiple myeloma. The main goal was to check safety and find the best dose. The study was terminated early, so we have limited information on how …
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental IDH drug trial halted early – what we know so far
Disease control Stopped earlyThis early-stage study tested an experimental drug called HMPL-306 in 46 adults with advanced blood cancers (like leukemia) that have a specific genetic change called an IDH mutation. The goal was to find a safe dose and check for side effects. The study was stopped early, so res…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control Stopped earlyThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug DFP-10917 tested in Late-Stage trial
Disease control Stopped earlyThis study tested a new drug called DFP-10917 in adults with acute myeloid leukemia (AML) that had returned or not responded after 2 to 4 prior treatments. Participants received either DFP-10917 or one of several standard chemotherapy combinations. The goal was to see if DFP-1091…
Phase 3 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem cell therapy for Crohn's fistulas: safety check ends early
Disease control Stopped earlyThis study tested the long-term safety and effectiveness of a stem cell treatment called darvadstrocel (Alofisel) for people with Crohn's disease and complex anal fistulas. Researchers planned to give one injection of the stem cells and follow 53 participants over several visits,…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental eye drops for GVHD dry eye show early promise but trial stops short
Disease control Stopped earlyThis study tested a new eye drop (rhPRG4) in 3 adults with moderate to severe dry eye from chronic graft-versus-host disease (GVHD), a complication of bone marrow transplants. The goal was to see if the drops safely improve dryness and eye surface damage. The trial was terminated…
Phase 1/2 • Sponsor: Lubris Bio Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Stopped earlyThis early-stage trial tested a new therapy for patients with acute myeloid leukemia (AML) that had returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack cancer cells carrying a specific marker (CD123).…
Phase 1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for leukemia patients too sick for chemo?
Disease control Stopped earlyThis phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve r…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
CAR-T therapy shows promise for Hard-to-Treat myeloma, but trial ends early
Disease control Stopped earlyThis phase 2 study tested a new CAR-T cell therapy called PHE885 in adults with relapsed and refractory multiple myeloma. The therapy targets a protein called BCMA on myeloma cells. The trial aimed to see how many patients responded, but it was terminated early. Results may still…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental combo for rare blood cancers hits roadblock
Disease control Stopped earlyThis study tested whether adding sabatolimab to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2). The trial aimed to see if the combination improved survival. However, the study was stopped early, so we …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental UC drug trial halted midway
Disease control Stopped earlyThis study tested a new drug called efavaleukin alfa in 221 adults with moderate to severe ulcerative colitis. The goal was to see if it could help patients achieve remission after 12 weeks of treatment. The trial was terminated early, so final results are limited, but the data m…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Food allergy drug safety trial ends early
Disease control Stopped earlyThis study looked at the long-term safety of ligelizumab, an injectable drug, in 163 people with food allergies who had already completed earlier Phase III studies. Participants received either 120 mg or 240 mg of ligelizumab every 4 weeks. The study was terminated, so full resul…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered immune cells take aim at Tough-to-Treat leukemia
Disease control Stopped earlyThis early-phase study tested a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia that returned or didn't respond to standard treatments. The therapy used the patient's own immune cells, modified to target two markers (CD19 and CD20) on leukemi…
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lupus drug trial halted early: what we know
Disease control Stopped earlyThis study tested a weekly injection called telitacicept against a placebo in 91 people with moderate-to-severe lupus. The goal was to see if the drug could reduce disease activity and allow lower steroid doses. However, the trial was terminated early, so we have less information…
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising combo for relapsed AML stalls as trial ends early
Disease control Stopped earlyThis phase 2 trial tested a combination of three oral drugs—decitabine, cedazuridine, and venetoclax—in adults whose acute myeloid leukemia (AML) came back after a donor stem cell transplant. The goal was to see if the drugs could kill cancer cells and achieve a complete remissio…
Phase 2 • Sponsor: Sanjay Mohan • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for CLL patients: umbralisib shows promise in early trial
Disease control Stopped earlyThis study tested the safety and effectiveness of the drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not received prior treatment. The goal was to see how many patients had their cancer shrink or disappear. The study was stopped early, but results st…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo for rare bone marrow cancer shows early promise, but trial halted
Disease control Stopped earlyThis study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a drug make milk allergy therapy safer and more effective?
Disease control Stopped earlyThis study tested whether adding dupilumab (a drug that reduces allergic reactions) to milk oral immunotherapy (gradually eating small amounts of milk) helps people with cow's milk allergy tolerate more milk with fewer side effects. The trial included 33 people aged 4 to 50 years…
Phase 2 • Sponsor: Andrew J Long, PharmD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control Stopped earlyThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising combo for relapsed leukemia in kids hits early hurdle
Disease control Stopped earlyThis study tested a drug called gilteritinib, which targets a specific genetic change in leukemia cells, combined with standard chemotherapy in children and young adults (ages 6 months to 21 years) whose acute myeloid leukemia (AML) had returned or not responded to treatment. The…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Stem cell transplant vs. standard care in myeloma relapse: a Head-to-Head trial
Disease control Stopped earlyThis study looked at whether a donor stem cell transplant (allogeneic) works better than standard drug therapy for people with multiple myeloma that came back after initial treatment. It included adults aged 18-70 with a compatible donor. The trial was stopped early, so results a…
Phase 3 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia
Disease control Stopped earlyThis study tested a two-drug combination (ibrutinib and venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatments. The goal was to see if starting with ibrutinib alone, then adding venetoclax, could safely clear t…
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental MCL drug trial halted early – what we know
Disease control Stopped earlyThis early-phase trial tested a new drug called TQB3909 in 19 people with mantle cell lymphoma that had returned or stopped responding to treatment. The goal was to find a safe dose and check for side effects. However, the study was terminated early, so we have limited informatio…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New biosimilar AVT16 takes on entyvio for ulcerative colitis
Disease control Stopped earlyThis phase 3 trial compared AVT16, a proposed biosimilar, to the approved drug Entyvio (vedolizumab) in 301 adults with moderate to severe ulcerative colitis. Participants received IV infusions over nearly a year. The study aimed to see if AVT16 works as well and is as safe as En…
Phase 3 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental AML combo trial halted early – what happened?
Disease control Stopped earlyThis early-phase trial tested an experimental drug called CWP232291 combined with the standard chemotherapy cytarabine in 15 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for signs of…
Phase 1/2 • Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Real-World tofacitinib study in ulcerative colitis ends early
Disease control Stopped earlyThis study looked at how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It measured symptom improvement and gut inflammation using stool samples. The study was small with 18 participants…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Diet study for Crohn's disease halted early – what we know
Disease control Stopped earlyThis study looked at whether an anti-inflammatory whole-food diet (rich in vegetables, fruits, and omega-3s, low in processed foods) could improve symptoms in people with mild to moderate Crohn's disease. It enrolled 28 adults and compared the diet to regular eating habits. The t…
Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
UV light zaps mouth sores in transplant patients?
Disease control Stopped earlyThis study tested whether shining a special UV light inside the mouth could help people with painful mouth sores caused by graft-versus-host disease after a stem cell transplant. Only 11 people took part, and the study was stopped early. The goal was to see if the light treatment…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental cell therapy for tough blood cancers put on hold
Disease control Stopped earlyThis early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Asthma drug safety check: dexpramipexole under Long-Term review
Disease control Stopped earlyThis study looked at the long-term safety of dexpramipexole in adults with severe eosinophilic asthma. Participants had already completed earlier phase 3 trials. The goal was to track side effects and asthma control over time. However, the study was terminated early, which may li…
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted midway: what it means for patients
Disease control Stopped earlyThis study tested a daily pill called dexpramipexole in 654 people with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal was to see if the drug could reduce severe asthma attacks over a year. However, the trial was terminat…
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Stopped earlyThis study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells…
Phase 2 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted: Dexpramipexole's promise unfulfilled
Disease control Stopped earlyThis Phase 3 trial tested dexpramipexole, an oral drug, in over 1,000 people with severe eosinophilic asthma that was not well controlled by standard treatments. The goal was to see if it could reduce severe asthma attacks over a year. However, the study was terminated early, so …
Phase 3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Targeted bone marrow radiation tested for myeloma relapse – trial halted early
Disease control Stopped earlyThis early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest …
Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kidney patients with Hard-to-Match immune systems
Disease control Stopped earlyThis study tested two drugs, daratumumab and belatacept, in 5 highly sensitized dialysis patients waiting for a kidney transplant. The goal was to safely reduce the antibodies that make it very hard to find a compatible donor kidney. The trial was stopped early, but it aimed to h…
Phase 2 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control Stopped earlyThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase 3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill for eczema shows promise in early trial – but study halted
Disease control Stopped earlyThis study tested an oral medication called SAR444656 in 70 adults with moderate to severe atopic dermatitis (eczema) that was not well controlled with topical treatments. Participants received one of three doses of the drug or a placebo for 16 weeks. The goal was to see if the d…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug shows promise for aggressive leukemia but carries serious clot risk
Disease control Stopped earlyThis study tested the drug ponatinib in 51 adults with a fast-growing form of chronic myeloid leukemia (CML) who had little or no prior treatment. The goal was to see if ponatinib could control the disease by blocking a protein that drives leukemia growth. However, the drug can c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Lupus kidney drug trial halted midway
Disease control Stopped earlyThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo aims to stop leukemia return in High-Risk patients
Disease control Stopped earlyThis study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in co…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Blood cancer drug fails to show promise in Post-Transplant trial
Disease control Stopped earlyThis early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose a…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug peresolimab tested for rheumatoid arthritis – study ends early
Disease control Stopped earlyThis study tested peresolimab, an experimental drug, in 491 adults with moderately-to-severely active rheumatoid arthritis who had not responded well to other treatments. The goal was to see if peresolimab could reduce joint pain and swelling better than a placebo. However, the s…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New eczema drug shows promise in early trial
Disease control Stopped earlyThis study tested a new medicine called LY3454738 in adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could improve skin symptoms like redness and itching. The trial included 234 participants and was stopped early. Results may help understand i…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill combo aims to fight tough bone marrow cancer
Disease control Stopped earlyThis study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental drug XmAb27564 tested for skin conditions – trial halted early
Disease control Stopped earlyThis early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerabi…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental CAR T-Cell therapy targets two proteins to fight tough lymphoma
Disease control Stopped earlyThis early-phase trial tested a new cell therapy called LUCAR-G39P in 11 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The main goals were to check s…
Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Promising combo for tough leukemia stalls: trial ends early
Disease control Stopped earlyThis phase 2 trial tested two drugs, CB-103 and venetoclax, in adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that had come back or not responded to treatment. The goal was to see if the combination could control the disease. However, the study was …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New MS drug trial for japanese patients shows promise but study stopped early
Disease control Stopped earlyThis study tested the drug natalizumab in 21 Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if injections under the skin every 4 weeks could reduce new brain lesions over 24 weeks, and to check safety for up to 48 weeks. The study was termin…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Promising UC drug trial halted early
Disease control Stopped earlyThis study tested a drug called bertilimumab in 32 adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce disease activity compared to a placebo. The trial was terminated early, so results are limited and no clear benefit was established.
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a common cholesterol drug tame inflammatory bowel disease?
Disease control Stopped earlyThis study tested whether statins, a common cholesterol drug, could change the gut bacteria in people with ulcerative colitis or Crohn's disease to a healthier type. The goal was to see if this change could reduce disease activity. The study was terminated early, so results are l…
Phase 2/3 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental CAR t therapy targets tough myeloma cases
Disease control Stopped earlyThis early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…
Phase 1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental drug aims to restore platelets in Heparin-Triggered disorder
Disease control Stopped earlyThis study tested an experimental drug called VLX-1005 in people with a rare condition where the blood thinner heparin causes a dangerous drop in platelets (cells that help blood clot). Participants received either VLX-1005 or a placebo alongside standard care. The goal was to se…
Phase 2 • Sponsor: Veralox Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Drug combo aims to control Slow-Growing lymphoma without chemo
Disease control Stopped earlyThis phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug BR108 tested in blood cancer patients – early results uncertain
Disease control Stopped earlyThis early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smart device helps arthritis patients stay on track
Disease control Stopped earlyThis study looked at whether a smart injection device (Smartclic) helps rheumatoid arthritis patients take their etanercept medication as prescribed. Researchers tracked 60 patients in Colombia for 40 weeks, measuring how often they used the device and how their symptoms changed.…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Psoriasis combo therapy trial ends early: what happened?
Disease control Stopped earlyThis study tested whether adding low-dose methotrexate to standard anti-TNF therapy could improve and extend the response in adults with moderate to severe psoriasis. The trial planned to enroll 78 participants but was terminated early. The main goal was to see how long patients …
Phase 4 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Early scope procedure fails to show clear benefit in severe pancreatitis trial
Disease control Stopped earlyThis study tested whether doing an early endoscopic ultrasound and removing any gallstones from the bile duct could help people with severe pancreatitis caused by gallstones. The trial planned to enroll many patients but was stopped early after only 27 participants. The main goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
AI-Powered diabetes coach could replace some doctor visits
Disease control Stopped earlyThis study tested a software called DreaMed Advisor Pro that automatically analyzes blood sugar and insulin pump data to suggest insulin dose adjustments. About 100 people with type 1 diabetes (ages 6-30) were split into two groups: one received recommendations directly from the …
Sponsor: Rabin Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising c. diff drug trial halted after just 3 patients
Disease control Stopped earlyThis study tested a new drug called REC-3964 to see if it could prevent repeat Clostridioides difficile (C. diff) infections in adults. Only 3 people were enrolled before the trial was stopped early. The goal was to check safety and whether the drug helped people stay infection-f…
Phase 2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Myeloma drug combo trial halted after only 2 patients
Disease control Stopped earlyThis study tested a new oral drug called narazaciclib combined with dexamethasone in people with multiple myeloma that returned or didn't respond to treatment. The goal was to find a safe dose and see if it could shrink the cancer. Only 2 patients were enrolled before the study w…
Phase 1/2 • Sponsor: Adriana Rossi • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Keytruda trial for untreated lymphoma halted early
Disease control Stopped earlyThis phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very l…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
HIV drug extension study halted early: what happened?
Disease control Stopped earlyThis study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…
Phase 2/3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental combo for tough blood cancers hits early hurdle
Disease control Stopped earlyThis early-stage trial tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine and venetoclax) in 25 people with relapsed or hard-to-treat acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. The study aimed to check…
Phase 1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New transplant method shows promise for tough blood cancers
Disease control Stopped earlyThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo for tough blood cancers halted early — only 4 patients enrolled
Disease control Stopped earlyThis study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Eczema drug trial halted early: what we know
Disease control Stopped earlyThis study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …
Phase 1/2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising drug for rare blood disorder trial halted early
Disease control Stopped earlyThis phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Pediatric GVHD drug combo trial halted early after just 2 kids enrolled
Disease control Stopped earlyThis study tested a drug called itacitinib combined with steroids to treat acute graft-versus-host disease (aGVHD) in children. aGVHD is a serious complication where donor immune cells attack the child's body after a stem cell transplant. The trial was stopped early after enrolli…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental immune cell therapy for AML shows promise but trial halted early
Disease control Stopped earlyThis study tested a treatment called MT-401, which uses specially trained immune cells from a donor to fight acute myeloid leukemia (AML) after a stem cell transplant. The goal was to see if these cells could prevent or treat relapse. The trial enrolled 92 people but was stopped …
Phase 2 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New program aims to boost HIV medication adherence for medicaid patients
Disease control Stopped earlyThis study tested a program to help Virginia Medicaid enrollees with HIV fill their antiretroviral prescriptions on time. The program offered support from providers, pharmacies, and community groups, with extra help for those who were very late refilling. Only 4 people enrolled b…
Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New anemia drug for MDS and myeloma patients shows early promise but trial halted
Disease control Stopped earlyThis study tested a daily pill called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to see if it was safe and could raise red blood cell levels, reducing the need for transfusions. The trial was terminated early afte…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spesolimab shows promise for Long-Term control of painful hand and foot pustules
Disease control Stopped earlyThis study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug shows promise for Long-Term ulcerative colitis control
Disease control Stopped earlyThis study tested a drug called efavaleukin alfa in people with moderate to severe ulcerative colitis who had already completed a previous study. The goal was to see if the drug is safe and works over a longer period, up to 104 weeks. The study was terminated early and enrolled o…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
HIV Antibody-Only therapy falls short in Long-Term trial
Disease control Stopped earlyThis study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…
Phase 2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a smartphone app replace doctor visits for arthritis patients?
Disease control Stopped earlyThis study tested whether using a smartphone app and a hand grip device could help people with rheumatoid arthritis manage their condition with fewer in-person doctor visits. About 94 adults with active rheumatoid arthritis were randomly assigned to use the app or continue standa…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control Stopped earlyThis study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…
Phase 2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody treatment aims to shield transplant patients from dangerous virus
Disease control Stopped earlyThis study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often …
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Crohn's drug trial halted early: what we know about ozanimod
Disease control Stopped earlyThis study was an extension of earlier trials, testing the drug ozanimod in people with moderately to severely active Crohn's disease. The goal was to see if the drug could help patients achieve remission and to track any side effects. The trial was terminated early, meaning it s…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 26, 2026 17:48 UTC
-
Experimental drug for rare blood disorder tested for long-term safety
Disease control Stopped earlyThis study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC
-
Experimental drug AMG 420 tested in Tough-to-Treat myeloma – early trial halted
Disease control Stopped earlyThis early-phase trial tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received the drug as a continuous 28-day IV infusion. The study aimed to find the safest dose and check …
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 16:30 UTC
-
Lupus drug combo tested in tiny trial – but study halted early
Disease control Stopped earlyThis phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 15:22 UTC
-
New drug combo for kids with tough leukemia shows promise but trial halted early
Disease control Stopped earlyThis trial tested the drug isatuximab, a targeted antibody, combined with standard chemotherapy in children aged 28 days to under 18 years whose acute leukemia had returned or stopped responding to treatment. The study aimed to see if the combination could help more children achi…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Experimental drug tested for Tough-to-Treat leukemia, but study stopped early
Disease control Stopped earlyThis phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 14:44 UTC
-
Myasthenia gravis drug trial halted early – only 6 patients enrolled
Disease control Stopped earlyThis study tested tolebrutinib, an oral drug, in adults with moderate-to-severe generalized myasthenia gravis. The trial was a Phase 3, double-blind, placebo-controlled study that planned to enroll many participants but was terminated early with only 6 people enrolled. Because it…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:27 UTC
-
CAR T-Cell trial for rare lymphoma halted after just one patient
Disease control Stopped earlyThis study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated e…
Phase 2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC
-
New automated insulin system tested in tiny trial
Disease control Stopped earlyThis study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only o…
Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
A single blood draw to unmask hidden infections in immune-weakened patients?
Diagnosis Stopped earlyThis trial tests a new blood test that uses metagenomic sequencing to identify any infection-causing microbe in cancer patients who develop febrile neutropenia—a serious fever that occurs when their immune system is weakened by treatment. The test aims to find the culprit faster …
Sponsor: Poitiers University Hospital • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Blood test may tame the tightrope walk of transplant drugs
Diagnosis Stopped earlyThis study tests whether a blood test called TruGraf can help doctors fine-tune immunosuppression medications in liver transplant recipients with autoimmune liver diseases like autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis. The test measures g…
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
AI reads eye photos to spot Diabetes-Related vision loss
Diagnosis Stopped earlyThis study tests whether an artificial intelligence program called NeoRetina can accurately detect diabetic retinopathy and diabetic macular edema from simple eye photographs. Researchers will compare the AI's analysis to standard exams by eye doctors. The goal is to see if this …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Tears may replace spinal taps for MS diagnosis
Diagnosis Stopped earlyThis study tests whether a tear sample can diagnose primary progressive multiple sclerosis (MS) as accurately as a spinal tap. Currently, doctors need to collect spinal fluid to confirm this type of MS, which is invasive and uncomfortable. Researchers will compare proteins in tea…
Sponsor: Lille Catholic University • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New Light-Based scanner aims to spot inflammation without needles
Diagnosis Stopped earlyThis study tested a new imaging tool called multispectral optoacoustic tomography (MSOT) to see if it could safely detect inflammation in people with graft-versus-host disease, Crohn's disease, or colitis. The device uses light and sound to create images of inflamed areas. The tr…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis Stopped earlyThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase 2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New imaging agent for lymphoma shows promise but trial stalls
Diagnosis Stopped earlyThis phase 3 trial tested a new radioactive imaging agent called [68Ga]Ga-PentixaFor to see if it could better detect lymphoma tumors compared to the standard PET scan. The study aimed to enroll adults with marginal zone lymphoma who had not yet been treated. However, the trial w…
Phase 3 • Sponsor: Pentixapharm AG • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis Stopped earlyThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a headband spot Alzheimer's? new study tests brain wave device
Diagnosis Stopped earlyThis study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention Stopped earlyThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Mesh may stop hernias after stoma closure, but study halted early
Prevention Stopped earlyThis pilot study tested whether placing a special mesh during ileostomy closure surgery could prevent hernias in people with inflammatory bowel disease. Only 8 patients were enrolled before the study was stopped. The main goal was to check safety, like infections or wound problem…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Prevention
Last updated Jun 27, 2026 09:09 UTC
-
Monthly HIV prevention pill tested in women – study halted early
Prevention Stopped earlyThis study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
New antibody shots aim to stop itchy eyes from birch pollen
Symptom relief Stopped earlyThis study tests two experimental drugs (REGN5713 and REGN5715) given alone or together to reduce eye allergy symptoms caused by birch pollen. About 350 adults with birch pollen allergy will receive the drugs or a placebo and then be exposed to pollen in a controlled setting. The…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can High-Tech toothbrushes protect gums in scleroderma?
Symptom relief Stopped earlyThis trial tests whether using a sonic toothbrush and a water flosser improves gum health better than a standard manual toothbrush in people with systemic sclerosis, a rare disease that often affects the mouth. About 20 adults with the condition will be randomly assigned to one o…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can a home exercise program help Hispanics/Latinos with MS?
Symptom relief Stopped earlyThis study tested whether a 4-month exercise program done at home could help Hispanic/Latino adults with multiple sclerosis (MS) improve their physical function, manage symptoms, and feel better overall. Participants worked with coaches via video calls and compared results to a c…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Can a scented fan ease breathlessness at the end of life?
Symptom relief Stopped earlyThis study looked at whether blowing a fan with aromatherapy on the face can help reduce breathlessness in people with terminal illness. The trial planned to enroll 26 adults who were near the end of life and had trouble breathing. Participants were randomly assigned to receive a…
Sponsor: Tsai-Wei Huang • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could a nerve pain drug and exercise ease long COVID fatigue?
Symptom relief Stopped earlyThis study tests whether the drug pregabalin, alone or with a rehabilitation program, can reduce chronic fatigue in people with post-COVID syndrome. Participants are adults aged 18 to 65 who had COVID-19 at least six months ago and still feel very tired. The trial compares four g…
Phase 2 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Pain pill showdown: ultracet vs. voltaren for back inflammation
Symptom relief Stopped earlyThis study compared two pain medications—Ultracet (tramadol/acetaminophen) and Voltaren (diclofenac)—in people with ankylosing spondylitis who were already taking disease-modifying anti-rheumatic drugs (DMARDs). The goal was to see which one worked better for pain relief over 8 w…
Phase 4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Steroid combo fails to show benefit for UC flares
Symptom relief Stopped earlyThis study looked at whether adding high-dose steroid pulses to the usual oral steroid course could help people with moderate ulcerative colitis flares achieve remission without needing other treatments. The trial was terminated early and enrolled 75 adults with left-sided or ext…
Phase 4 • Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Exercise program for myeloma patients shows promise but study ends early
Symptom relief Stopped earlyThis study looked at whether a supervised exercise program could help improve quality of life and reduce fatigue in people under 65 with multiple myeloma who had a stem cell transplant. Participants were randomly assigned to either an exercise group or a control group. The study …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Eczema cream study halted after just 3 volunteers
Symptom relief Stopped earlyThis small study tested an over-the-counter cream for atopic dermatitis (eczema) in just 3 people. Researchers looked at skin bacteria, hydration, and barrier function to see if the cream helped. The study was terminated early, so results are very limited.
Phase 1 • Sponsor: Good Molecules, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Personalized exercise trial for chronic fatigue ends early
Symptom relief Stopped earlyThis study tested whether a personalized exercise program could reduce fatigue in people with chronic fatigue syndrome. About 101 participants were planned, but the trial was terminated early. The approach involved tailoring aerobic and resistance exercises based on weekly fatigu…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain zaps for pain and fatigue: a quick fix?
Symptom relief Stopped earlyThis study looked at whether a brief, noninvasive brain stimulation technique called tDCS could immediately reduce pain and improve function in people with fibromyalgia or chronic fatigue syndrome. About 20 participants received one session, and researchers measured changes in pa…
Sponsor: Hospital Donostia • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Exercise for IBD fatigue: tiny trial ends early
Symptom relief Stopped earlyThis study looked at whether moderate physical activity three times a week could reduce chronic fatigue in people with inflammatory bowel disease (IBD). Fatigue affects about 40% of IBD patients and can lower quality of life. The trial planned to compare a group that added extra …
Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Pain relief drug trial for mast cell syndrome stalls early
Symptom relief Stopped earlyThis Phase 2 trial tested whether FSD201 tablets could reduce chronic pain in adults with mast cell activation syndrome. The study planned to enroll many participants but was terminated early with only 2 people. No results are available to show if the drug works or is safe.
Phase 2 • Sponsor: Quantum Biopharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Omega-3 skin cream shows promise for eczema relief in small study
Symptom relief Stopped earlyThis early study tested whether a daily omega-3 serum and cream could ease eczema symptoms and change the balance of bacteria on the skin. Seven adults with eczema applied the products for six weeks and reported their symptom severity using a questionnaire. The study also checked…
Sponsor: SCF Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Psoriasis drug trial for sensitive areas halted early
Symptom relief Stopped earlyThis study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New injection targets psoriatic arthritis pain in small trial
Symptom relief Stopped earlyThis early-stage study tested the safety of an experimental drug called Allocetra, injected directly into the joint, for people with psoriatic arthritis. Only 5 participants were enrolled. The main goal was to check for side effects, with some initial data on pain relief. The stu…
Phase 1 • Sponsor: Enlivex Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Laser hope for scars and scleroderma fizzles in tiny trial
Symptom relief Stopped earlyThis study tested whether a special laser could improve scars and skin hardening from scleroderma. Only 6 people took part, and the study was stopped early. Researchers measured scar changes using a standard scale, but the small size and early termination mean we cannot draw firm…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New eczema pill shows promise in Mid-Stage trial
Symptom relief Stopped earlyThis study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve with topical creams. The goal was to see if it reduces skin redness, swelling, and itchiness over 16 weeks. The trial involved 229 particip…
Phase 2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Hay fever education trial fizzles out: did extra lessons help?
Symptom relief Stopped earlyThis study tested whether teaching teens and young adults (ages 14-29) the correct way to use nasal sprays for hay fever would improve their symptoms compared to standard care. The trial was terminated early and enrolled only 18 participants. The goal was to see if repeat educati…
Sponsor: Murdoch Childrens Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Taste and smell training offers hope for chemo patients
Symptom relief Stopped earlyThis study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program involved exercises to retrain the nose and tongue. Only 5 people enrolled before the study ende…
Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Buddy system for IBD teens: does a mentor make a difference?
Symptom relief Stopped earlyThis study looked at whether having a peer mentor—an older teen or young adult who also has IBD—can help youth ages 10-17 better manage their disease and improve their quality of life. Participants were randomly assigned to either a year-long mentoring program or educational acti…
Sponsor: Kelly Boone • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Eczema cream aims to end sleepless nights
Symptom relief Stopped earlyThis study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…
Phase 4 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Can hand exercises and electrical stimulation ease MS sensory problems?
Symptom relief Stopped earlyThis study tested a rehabilitation program for hand sensitivity problems in people with multiple sclerosis. The program used TENS (a mild electrical stimulation device) and hand exercises to improve the ability to feel and recognize objects. The goal was to improve quality of lif…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
MS fatigue drug study halted early
Symptom relief Stopped earlyThis study aimed to see if the drug ozanimod could help reduce fatigue in people with multiple sclerosis (MS). Researchers planned to follow 26 adults with MS for three months, measuring fatigue using special questionnaires and brain scans. The study was terminated early, so resu…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Experimental shot for Cold-Triggered hives tested, but trial stopped early
Symptom relief Stopped earlyThis early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…
Phase 1/2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
RA patients paired with buddies to boost Well-Being
Symptom relief Stopped earlyThis study tested a program where people with rheumatoid arthritis (RA) were paired with a trained peer supporter for up to 6 months. The goal was to see if sharing experiences and support could improve daily function, medication adherence, and symptoms like pain and fatigue. The…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Brain fatigue after thyroid disease: immune system may be to blame
Knowledge-focused Stopped earlyThis study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to f…
Sponsor: Vastra Gotaland Region • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
20-Year review of lymphoma care reveals Real-World treatment success
Knowledge-focused Stopped earlyThis study examines the medical records of 400 people diagnosed with various types of lymphoma at a French hospital between 1999 and 2018. Researchers want to see how long patients survived and whether the care they received matched what medical guidelines recommend. The goal is …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can pressurized oxygen tame blood sugar spikes?
Knowledge-focused Stopped earlyThis study asks whether a single session of hyperbaric oxygen therapy (HBOT) can lower blood sugar or change glucagon levels in people with type 1 or type 2 diabetes. Participants will undergo one HBOT session and one control session (sitting in a room at normal pressure), while …
Sponsor: Legacy Health System • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Ultrasound could uncover hidden vascular risks in turner syndrome
Knowledge-focused Stopped earlyThis study is looking at whether yearly ultrasound scans can detect blood vessel abnormalities throughout the body in women with Turner syndrome, not just in the heart area. Turner syndrome is a genetic condition that increases the risk of serious vascular problems, which can sho…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Study aims to predict drug failure in rare blood cancer
Knowledge-focused Stopped earlyThis study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first t…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Leukemia drug pill tested against IV version – but study halted early
Knowledge-focused Stopped earlyThis very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Hidden toll of diabetes caregiving revealed in new study
Knowledge-focused Stopped earlyThis study looks at how caring for a child recently diagnosed with type 1 diabetes affects caregivers' work, daily life, and well-being. About 100 Canadian caregivers will fill out online questionnaires about their productivity, healthcare use, and quality of life. No treatment i…
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Eczema study sheds light on skin disease and treatment options
Knowledge-focused Stopped earlyThis study aimed to better understand eczema by collecting data, blood, and skin samples from 69 participants across Canada. It also compared two types of light therapy (broadband vs narrowband UVB) to see which works better for treating eczema. The study was terminated early, so…
Sponsor: Women's College Hospital • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Biopsy tolerance study ends early – what we know
Knowledge-focused Stopped earlyThis study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New MRI scans reveal hidden brain changes after first MS symptoms
Knowledge-focused Stopped earlyThis study used a special MRI technique to look at tiny brain changes in people who recently had a first episode of symptoms that could lead to multiple sclerosis (MS). Researchers compared 84 participants (patients and healthy controls) to see if early memory problems are linked…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
Knowledge-focused Stopped earlyThis study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study explores simple tests to replace colonoscopies for colitis patients
Knowledge-focused Stopped earlyThis study aimed to see if certain substances in stool and blood can predict whether the gut lining has healed in people with moderate to severe ulcerative colitis. Researchers planned to measure these markers in 62 adults before and after treatment. The study was terminated earl…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a common virus trigger thyroid troubles?
Knowledge-focused Stopped earlyThis study investigated whether polyomaviruses (a type of common virus) are found more often in people with autoimmune thyroiditis or goiters. Researchers compared virus presence in blood, urine, and thyroid tissue from 49 patients undergoing thyroid surgery. The goal was to see …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused Stopped earlyThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Antibiotic resistance explored in myeloma stem cell transplants
Knowledge-focused Stopped earlyThis study aimed to find out how common antibiotic resistance is in multiple myeloma patients receiving a stem cell transplant. Researchers planned to collect data from 124 adults to help design future studies on preventing infections. The study was stopped early, so results are …
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Leukemia relapse study halted: could a blood test have predicted it?
Knowledge-focused Stopped earlyThis study aimed to see if a sensitive molecular test could predict relapse in adults with acute myeloid leukemia (AML) who had a stem cell transplant. Researchers planned to follow 303 patients in remission, comparing outcomes between those with and without detectable disease ma…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Yeast study in rare autoimmune disease terminated early
Knowledge-focused Stopped earlyThis study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Painkiller showdown: which is safer for the heart?
Knowledge-focused Stopped earlyThis study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…
Phase 4 • Sponsor: Platelet and Thrombosis Research, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood test may predict dangerous MS rebound after stopping popular drug
Knowledge-focused Stopped earlyThis small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting M…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Lymphoma Patients' vaccine response under scrutiny
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine works in adults with B-cell non-Hodgkin lymphoma, especially those who received a common treatment called anti-CD20 monoclonal antibodies in the past year. Researchers compared antibody and T-cell responses between treated and un…
Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists investigate mpox in severely weakened immune systems
Knowledge-focused Stopped earlyThis study looked at how the mpox virus spreads and how the immune system responds in people with advanced HIV. Researchers tracked the virus in different body samples and measured immune markers to better understand severe illness. The goal is to use these findings to improve tr…
Sponsor: Centers for Disease Control and Prevention • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Nickel allergy and knee surgery: no big difference found?
Knowledge-focused Stopped earlyThis study looked at whether people with nickel allergy do better with special nickel-free knee implants. Researchers compared standard implants to nickel-free ones in 9 patients with self-reported nickel sensitivity. The goal was to see if nickel allergy affects pain, function, …
Sponsor: Rush University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Web tool aims to boost HIV testing among black women in the south
Knowledge-focused Stopped earlyThis study tested a web-based program to help Black women in Texas use HIV and STI home tests and connect to treatment or PrEP. The program included five sessions with goal-setting and action plans. Only 31 women enrolled before the study was stopped early, so the findings are li…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New tool aims to help seniors with dementia make safer choices about guns
Knowledge-focused Stopped earlyThis pilot study tested a decision aid designed to help older adults with early dementia or depression think about safer ways to store firearms at home. Only 5 people took part, and the study was ended early. The goal was to see if the tool was practical and acceptable, and wheth…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Superhero training for food allergy safety falls short
Knowledge-focused Stopped earlyThis study aimed to help children aged 6-8 from low-income families learn how to avoid foods they are allergic to. The program used fun, hands-on activities to teach safety skills. The study was stopped early, so we don't have clear results on whether it worked.
Sponsor: Kent State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused Stopped earlyThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused Stopped earlyThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
What sets off MS Flare-Ups? scientists investigate stress and hormones
Knowledge-focused Stopped earlyThis study looked at how stress, hormonal cycles, illness, and missed medications might affect when symptoms appear or get worse in women with relapsing-remitting multiple sclerosis (RR-MS). Researchers planned to track 80 women over time, recording daily symptom changes. The stu…
Sponsor: University of Louisville • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Preterm Kids' lungs under the microscope: study halted early
Knowledge-focused Stopped earlyThis study aimed to track lung function in children born prematurely (before 37 weeks) aged 3 to 5 years, comparing them to full-term children. Researchers used breathing tests and samples to look for early signs of asthma and allergies. The study was terminated early, so results…
Sponsor: Stefania La Grutta, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Massive myeloma registry ends early, but data may still inform care
Knowledge-focused Stopped earlyThis study was a large registry that followed over 3,000 people newly diagnosed with multiple myeloma to understand how the disease is managed in everyday practice. Participants received standard treatments prescribed by their own doctors, and researchers collected information on…
Sponsor: Celgene • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused Stopped earlyThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused Stopped earlyThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
MRI scans aim to predict tysabri success in MS patients
Knowledge-focused Stopped earlyThis study looked at whether special MRI scans can detect early brain changes in people with multiple sclerosis who are starting treatment with Tysabri. Researchers planned to follow 70 patients for two years, comparing MRI images before and after treatment. The goal was to find …
Phase 4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Breathlessness mystery: can a finger device predict side effects in myeloma treatment?
Knowledge-focused Stopped earlyThis study aimed to find out why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved finger device called EndoPAT to check blood vessel health and tracked symptoms through surveys. The study enrolled 50 adu…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Small study tests blood sugar targets to prevent lows during exercise in type 1 diabetes
Knowledge-focused Stopped earlyThis study looked at people with type 1 diabetes who use do-it-yourself automated insulin delivery (DIY-AID) systems. Researchers wanted to find the best blood glucose target to set 60 minutes before moderate aerobic exercise (like cycling) to keep blood sugar stable and avoid da…
Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Ibrutinib heart risks under the microscope: can we predict them?
Knowledge-focused Stopped earlyThis study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Insulin's hidden role in psoriasis uncovered
Knowledge-focused Stopped earlyThis study looked at how insulin works in the skin of people with plaque psoriasis who are also overweight or have prediabetes. Researchers took small skin samples from both psoriasis patches and healthy skin to measure insulin activity. The goal was to understand if insulin acts…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Can your personality change your diabetes genes?
Knowledge-focused Stopped earlyThis study looked at whether people with type 1 or type 2 diabetes who have a 'Type A' (impatient, proactive) or 'Type B' (calm, slow) personality show different genetic markers linked to inflammation and stress. Researchers planned to collect blood samples and have participants …
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Eczema Drug's skin secrets under the microscope
Knowledge-focused Stopped earlyThis study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, whi…
Phase 2/3 • Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Hospital study aims to clear up penicillin allergy confusion
Knowledge-focused Stopped earlyThis study tested a new approach to safely remove incorrect penicillin allergy labels from hospitalized patients. Many people are wrongly labeled as allergic, which limits their treatment options. The goal was to see how often the allergy label could be removed after proper evalu…
Sponsor: Althaia Xarxa Assistencial Universitària de Manresa • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused Stopped earlyThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Lupus and COVID vaccines: immune response under the microscope
Knowledge-focused Stopped earlyThis study aimed to understand how the COVID-19 vaccine impacts the immune system in people with lupus, a chronic autoimmune disease. Researchers planned to enroll lupus patients to measure their immune response to the vaccine and see if lupus disease activity or treatments affec…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Light therapy study sheds light on immune changes in transplant complication
Knowledge-focused Stopped earlyThis study looked at how extracorporeal photopheresis (ECP) — a treatment that uses light to modify a patient's own blood cells — affects the immune system in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Only 8 people were en…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Experimental eczema drug tested in healthy people – but trial halted
Knowledge-focused Stopped earlyThis was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with…
Phase 1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Wearable device aims to track MS progression from home
Knowledge-focused Stopped earlyThis study tested a wearable device called Syde® in 86 people with multiple sclerosis. Participants wore the device for one month every six months over two years. The goal was to see if the device's activity data matches standard clinic tests like walking speed and disability sco…
Sponsor: SYSNAV • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Tablet teaching for diabetes: a High-Tech hope for new patients?
Knowledge-focused Stopped earlyThis study tested whether using a bedside tablet with interactive education modules helps people newly diagnosed with type 1 diabetes learn more than standard paper-based materials. The trial planned to enroll 28 patients but was terminated early. Researchers measured diabetes kn…
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Filmed consultations aim to decode eczema discomfort in babies under 6 months
Knowledge-focused Stopped earlyThis study filmed consultations between dermatologists and infants under 6 months old with atopic dermatitis (eczema). Researchers analyzed the videos to identify specific behaviors that might indicate discomfort, since standard itch assessment scales don't work for babies this y…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may help some ANCA patients skip unnecessary drugs
Knowledge-focused Stopped earlyThis study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initia…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Elderly arthritis study reveals hidden health risks
Knowledge-focused Stopped earlyThis study aimed to understand how age influences serious health issues like infections, cancer, heart disease, and bone fractures in people with rheumatoid arthritis. Researchers compared patients over 65 with younger adults (18-50) who had the same disease. The study was stoppe…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Sjögren's dry eye study probes corneal nerve damage
Knowledge-focused Stopped earlyThis study aimed to find out how many people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. The study w…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gene hunt in leukemia: what IDH mutations mean for patients
Knowledge-focused Stopped earlyThis study aimed to find how often IDH1 and IDH2 gene mutations occur in adults with acute myeloid leukemia (AML) in China, and whether those mutations affect a patient's chance of relapse or survival. Researchers planned to analyze stored leukemia samples from over 1,000 patient…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Body clock may predict asthma attacks
Knowledge-focused Stopped earlyThis study looked at whether proteins that control our body's daily rhythms (clock proteins) can predict how severe asthma will get. Researchers monitored these proteins in the blood and sputum of 50 adults with severe eosinophilic asthma before and during treatment with mepolizu…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Lab study explores how JAK inhibitors affect immune cells in arthritis
Knowledge-focused Stopped earlyThis study looked at how JAK-STAT inhibitors, a type of drug used for rheumatoid arthritis, affect certain immune cells called regulatory B cells. Researchers analyzed blood samples from 27 patients to see if these drugs could boost anti-inflammatory functions. The study was term…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists probe immune cells in arthritic joints for clues
Knowledge-focused Stopped earlyThis pilot study analyzed special immune cells called regulatory T cells (Tregs) in the joint fluid of 19 people with rheumatoid arthritis during a flare-up. Researchers compared these cells to Tregs in the blood to understand how they behave in inflamed joints. No treatment was …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny bone marker study in myeloma ends early
Knowledge-focused Stopped earlyThis study aimed to track four bone-related markers in the blood and urine of multiple myeloma patients receiving standard bisphosphonate therapy. Only 3 people enrolled before the study was terminated. It was designed to observe changes over 12 months, not to test a new treatmen…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused Stopped earlyThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused Stopped earlyThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC
-
Can a simple ultrasound replace MRI for Crohn's? small study investigates
Knowledge-focused Stopped earlyThis study looked at using point-of-care ultrasound (POCUS) to assess small bowel Crohn's disease. Researchers interviewed doctors, nurses, and patients to understand if POCUS could be useful in the NHS. They also compared how POCUS and MRI scans affected doctors' treatment decis…
Sponsor: Nottingham University Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:32 UTC